上海，2026年5月18日 - 藥明康德近日宣布公司入選2026道瓊斯領先全球指數（Dow Jones Best-in-Class World Index，原道瓊斯可持續發展世界指數），該指數基于企業長期可持續發展標準，評選出全球各行業處于領先水平的公司。這一認可充分彰顯了公司在推動可持續發展和踐行負責任商業實踐方面的堅定承諾。

道瓊斯領先全球指數由標普全球通過企業可持續發展評估（CSA）進行評選。該評估體系采用行業特定視角，重點關注對長期發展具有實質性影響的經濟、環境和社會議題。該指數僅納入在各自領域排名前列的企業。

“很榮幸入選道瓊斯領先全球指數，這體現了藥明康德將可持續發展深度融入企業戰略和日常運營的不懈努力。”藥明康德聯席首席執行官兼可持續發展委員會主席楊青博士表示：“我們將持續加強全球化能力建設和產能投放，與行業同仁攜手共建更健康、更可持續的未來，早日實現‘讓天下沒有難做的藥，難治的病’的偉大愿景。”

作為創新的賦能者、客戶信賴的合作伙伴以及全球健康產業的貢獻者，藥明康德和大多數客戶一樣，積極踐行對可持續發展的承諾。截至目前，公司連續五年獲得MSCI ESG領導力評級，并在最新的評估中首次獲得“AAA”最高評級；連續四年入選標普全球《可持續發展年鑒》；連續三年入選富時羅素社會責任指數系列；連續兩年獲得EcoVadis企業社會責任評級“金牌”認證；連續兩年獲得CDP水安全最高評級“A”級，并首次獲得CDP氣候變化最高評級“A”級；連續兩年在ISS ESG企業評級中獲得“Prime”表彰。

此外，為進一步深化可持續發展承諾，藥明康德持續拓展全球責任實踐。公司溫室氣體減排近期目標成功通過了SBTi審核認證。同時，公司已加入聯合國全球契約組織（UNGC），承諾支持全球契約十項原則；并加入制藥供應鏈倡議（PSCI），成為PSCI供應商合作伙伴。

關于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）是全球醫藥及生命科學行業值得信賴的合作伙伴和重要貢獻者，致力于通過提供一體化、端到端的新藥研發和生產服務，推動全球醫藥健康創新。公司在亞洲、歐洲、北美等地均設有運營基地，依托獨特的“CRDMO”業務模式，不斷降低研發門檻，助力客戶提升研發效率，為患者帶來突破性的治療方案。目前，公司的賦能平臺正承載著來自全球30多個國家的合作伙伴的研發創新項目，致力于將更多新藥、好藥帶給全球病患，早日實現“讓天下沒有難做的藥，難治的病”的愿景。更多信息，請訪問公司網站：www.wuxiapptec.com

WuXi AppTec Recognized as a Top-Performing Company on 2026 Dow Jones Best-in-Class World Index

SHANGHAI, May 17, 2026 - WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been selected for the 2026 Dow Jones Best-in-Class World Index (DJ BIC World Index, formerly Dow Jones Sustainability World Index), which recognizes the top-performing companies in each industry on long-term sustainability criteria. This recognition reflects progress that WuXi AppTec has made in integrating responsible sustainability practices across its operations and strategies.

The Dow Jones Best-in-Class World Index, administered by S&P Global through its Corporate Sustainability Assessment (CSA), selects companies that rank in the top tier of their respective industries on long-term economic, environmental, and social criteria. The CSA evaluates companies through the lens of their specific industries, weighting sustainability factors by their relevance to long-term performance. Index inclusion is reserved for companies that rank in the top tier of their sector.

“We are honored to be included on the Dow Jones Best-in-Class World Index, which reflects WuXi AppTec’s continued efforts to embed sustainability into our corporate strategy and daily operations,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s Sustainability Committee. “We will continue to strengthen our global capabilities and capacity as a trusted partner to the global pharmaceutical industry, and to build a world where ‘every drug can be made, and every disease can be treated.’”

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates sustainability throughout its operations in alignment with the values of its customers and partners. The Company’s sustainability performance has received top-tier ratings across every major independent ESG framework:

• Has received the MSCI ESG leadership rating for five consecutive years, achieving its first “AAA” rating in the most recent assessment.

• Has been included in the S&P Global Sustainability Yearbook for four consecutive years.

• Has been listed in the FTSE4Good Index Series for three consecutive years.

• Has been awarded a “Gold” medal in sustainability by EcoVadis for the second consecutive year.

• Has maintained the highest “A” rating in CDP Water Security for two consecutive years and achieved the highest “A” rating in CDP Climate Change for the first time.

• Has been awarded “Prime” Status in the ISS ESG Corporate Rating for two consecutive years.

Furthering its sustainability commitments, WuXi AppTec’s near-term greenhouse gas emissions reduction targets have been validated by the Science Based Targets initiative (SBTi). The Company is also a participant in the United Nations Global Compact (UNGC), supporting its ten principles, and serves as a supplier partner to the Pharmaceutical Supply Chain Initiative (PSCI).

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

免責聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。